Published in J Virol on January 07, 2009
Herpes virus fusion and entry: a story with many characters. Viruses (2012) 2.05
Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS Pathog (2011) 1.53
Regulation of herpes simplex virus gB-induced cell-cell fusion by mutant forms of gH/gL in the absence of gD and cellular receptors. MBio (2013) 1.07
A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. J Virol (2010) 1.02
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther (2012) 1.02
HSV Recombinant Vectors for Gene Therapy. Open Virol J (2010) 0.99
Novel mutations in gB and gH circumvent the requirement for known gD Receptors in herpes simplex virus 1 entry and cell-to-cell spread. J Virol (2012) 0.91
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Mol Ther Oncolytics (2015) 0.85
Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility. Gene Ther (2015) 0.83
Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells. Mol Ther (2010) 0.83
Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. Gene Ther (2012) 0.82
Induction of conformational changes at the N-terminus of herpes simplex virus glycoprotein D upon binding to HVEM and nectin-1. Virology (2013) 0.81
Mechanism of HSV infection through soluble adapter-mediated virus bridging to the EGF receptor. Virology (2011) 0.81
Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. Gene Ther (2016) 0.78
Herpesvirus Entry Mediator on Radiation-Resistant Cell Lineages Promotes Ocular Herpes Simplex Virus 1 Pathogenesis in an Entry-Independent Manner. MBio (2015) 0.77
Retargeting of herpes simplex virus (HSV) vectors. Curr Opin Virol (2016) 0.76
Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus. J Virol (2016) 0.75
A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. J Virol (2015) 0.75
The soluble amino-terminal region of HVEM mediates efficient herpes simplex virus type 1 infection of gD receptor-negative cells. Virol J (2012) 0.75
Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell (1996) 9.03
Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science (1998) 7.89
A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells. J Virol (1988) 7.80
A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82
Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. J Virol (1988) 5.84
Crystal structure of glycoprotein B from herpes simplex virus 1. Science (2006) 5.57
Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell (2001) 4.44
A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. J Virol (1992) 4.12
Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J Virol (1998) 3.94
Nectin/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein. J Cell Biol (1999) 3.47
Roles for endocytosis and low pH in herpes simplex virus entry into HeLa and Chinese hamster ovary cells. J Virol (2003) 3.14
Excretion of non-infectious virus particles lacking glycoprotein H by a temperature-sensitive mutant of herpes simplex virus type 1: evidence that gH is essential for virion infectivity. J Gen Virol (1988) 3.11
Pseudorabies virus glycoproteins gII and gp50 are essential for virus penetration. J Virol (1991) 3.00
Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J (2005) 2.95
Pseudorabies virus envelope glycoproteins gp50 and gII are essential for virus penetration, but only gII is involved in membrane fusion. J Virol (1992) 2.93
Directed egress of animal viruses promotes cell-to-cell spread. J Virol (2002) 2.72
PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell (2008) 2.49
Glycoprotein D of herpes simplex virus encodes a domain which precludes penetration of cells expressing the glycoprotein by superinfecting herpes simplex virus. J Virol (1990) 2.17
Cellular and viral requirements for rapid endocytic entry of herpes simplex virus. J Virol (2004) 2.17
Glycoprotein D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1. J Virol (2005) 2.07
Nectin2alpha (PRR2alpha or HveB) and nectin2delta are low-efficiency mediators for entry of herpes simplex virus mutants carrying the Leu25Pro substitution in glycoprotein D. J Virol (2000) 2.01
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J Virol (2005) 1.85
Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface. J Virol (2003) 1.78
Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host Microbe (2007) 1.78
Envelope glycoprotein gp50 of pseudorabies virus is essential for virus entry but is not required for viral spread in mice. J Virol (1993) 1.77
The pro-fusion domain of herpes simplex virus glycoprotein D (gD) interacts with the gD N terminus and is displaced by soluble forms of viral receptors. Proc Natl Acad Sci U S A (2005) 1.73
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Virology (1990) 1.49
Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1. Mol Ther (2001) 1.47
Search for polymorphisms in the genes for herpesvirus entry mediator, nectin-1, and nectin-2 in immune seronegative individuals. J Infect Dis (2001) 1.47
Mapping of herpes simplex virus 1 genes with mutations which overcome host restrictions to infection. Proc Natl Acad Sci U S A (1994) 1.46
Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism. Proc Natl Acad Sci U S A (2004) 1.43
Role of essential glycoproteins gII and gp50 in transneuronal transfer of pseudorabies virus from the hypoglossal nerves of mice. J Virol (1993) 1.41
Different receptors binding to distinct interfaces on herpes simplex virus gD can trigger events leading to cell fusion and viral entry. Virology (2006) 1.41
FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells. J Immunol (2000) 1.39
Potential nectin-1 binding site on herpes simplex virus glycoprotein d. J Virol (2005) 1.39
Effects of herpes simplex virus on structure and function of nectin-1/HveC. J Virol (2002) 1.20
Role of nectin in organization of tight junctions in epithelial cells. Genes Cells (2002) 1.18
Mutations in herpes simplex virus glycoprotein D distinguish entry of free virus from cell-cell spread. J Virol (2000) 1.17
Nectin-1/HveC Mediates herpes simplex virus type 1 entry into primary human sensory neurons and fibroblasts. J Neurovirol (2005) 1.08
Equine herpesvirus 1 enters cells by two different pathways, and infection requires the activation of the cellular kinase ROCK1. J Virol (2007) 1.04
Random mutagenesis of the gene encoding a viral ligand for multiple cell entry receptors to obtain viral mutants altered for receptor usage. Proc Natl Acad Sci U S A (2004) 1.02
Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J Virol (2000) 0.98
Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins. Proc Natl Acad Sci U S A (2007) 0.98
Herpesvirus entry mediator HVEM mediates cell-cell spread in BHK(TK-) cell clones. J Virol (1998) 0.93
Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology (2006) 0.87
Inactivation of herpes simplex type 1 gene vector on immobilized metal affinity chromatography: oxidative damage by hydroxyl free radicals and its prevention. Biotechnol Bioeng (2006) 0.81
A rapid and sensitive cellular enzyme-linked immunoabsorbent assay (CELISA) for the detection and quantitation of antibodies against cell surface determinants. I. A comparison of cell fixation and storage techniques. J Immunol Methods (1992) 0.79
Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A. Gene Ther (2000) 0.78
Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature (2002) 45.19
Proteome survey reveals modularity of the yeast cell machinery. Nature (2006) 20.77
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol (2011) 4.83
A new transgene reporter for in vivo magnetic resonance imaging. Nat Med (2005) 2.85
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 2.35
Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer (2003) 2.08
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann Neurol (2002) 1.74
An HSV vector system for selection of ligand-gated ion channel modulators. Nat Methods (2007) 1.57
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther (2004) 1.56
Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol (2005) 1.47
Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol (2006) 1.43
Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol (2002) 1.40
HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain (2006) 1.32
Gene therapy for pain: results of a phase I clinical trial. Ann Neurol (2011) 1.31
Progress in gene therapy for neurological disorders. Nat Rev Neurol (2013) 1.22
Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes (2002) 1.14
Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain (2007) 1.13
Protein kinase C epsilon contributes to basal and sensitizing responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons. Eur J Neurosci (2008) 1.12
Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of virus growth. Virology (2008) 1.11
HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol Ther (2003) 1.07
Adverse effects of adenovirus-mediated gene transfer of human transforming growth factor beta 1 into rabbit knees. Arthritis Res Ther (2003) 1.07
Soluble V domain of Nectin-1/HveC enables entry of herpes simplex virus type 1 (HSV-1) into HSV-resistant cells by binding to viral glycoprotein D. J Virol (2006) 1.07
Effects of transgene-mediated endomorphin-2 in inflammatory pain. Eur J Pain (2008) 1.06
Equine herpesvirus 1 enters cells by two different pathways, and infection requires the activation of the cellular kinase ROCK1. J Virol (2007) 1.04
Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain (2004) 1.04
The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem Biol (2013) 1.04
A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. J Virol (2010) 1.02
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther (2012) 1.02
Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Res (2012) 1.01
The relationship of herpes simplex virus latency associated transcript expression to genome copy number: a quantitative study using laser capture microdissection. J Neurovirol (2002) 1.01
Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin. Hum Gene Ther (2009) 1.01
Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther (2005) 1.00
Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother (2009) 0.98
Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes (2004) 0.97
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res (2010) 0.97
Engineering HSV-1 vectors for gene therapy. Methods Mol Biol (2014) 0.96
Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. Mol Ther (2005) 0.96
Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells. Vet Microbiol (2009) 0.95
Equine herpesvirus 1 utilizes a novel herpesvirus entry receptor. J Virol (2005) 0.95
Premature aging-related peripheral neuropathy in a mouse model of progeria. Mech Ageing Dev (2011) 0.94
Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther (2003) 0.93
Gene delivery using herpes simplex virus vectors. DNA Cell Biol (2002) 0.92
Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV. Clin Cancer Res (2012) 0.92
Novel mutations in gB and gH circumvent the requirement for known gD Receptors in herpes simplex virus 1 entry and cell-to-cell spread. J Virol (2012) 0.91
Gene therapy for the treatment of chronic peripheral nervous system pain. Neurobiol Dis (2012) 0.91
Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol Ther (2004) 0.91
Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models. J Neurovirol (2011) 0.91
Development of replication-defective herpes simplex virus vectors. Methods Mol Med (2002) 0.90
Gene therapy: novel treatments for polyneuropathy and chronic pain. Curr Neurol Neurosci Rep (2004) 0.90
Equus caballus major histocompatibility complex class I is an entry receptor for equine herpesvirus type 1. J Virol (2010) 0.89
Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats. J Urol (2005) 0.89
Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. Eur J Neurosci (2003) 0.89
The transcription factor Sox11 promotes nerve regeneration through activation of the regeneration-associated gene Sprr1a. Exp Neurol (2011) 0.88
Gene transfer of human manganese superoxide dismutase protects small intestinal villi from radiation injury. J Gastrointest Surg (2003) 0.88
HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice. Mol Ther (2006) 0.88
Herpes simplex virus-mediated expression of Pax3 and MyoD in embryoid bodies results in lineage-Related alterations in gene expression profiles. Stem Cells (2008) 0.87
Suppression of detrusor-sphincter dyssynergia by herpes simplex virus vector mediated gene delivery of glutamic acid decarboxylase in spinal cord injured rats. J Urol (2010) 0.87
Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology (2006) 0.87
The stable 2.0-kilobase intron of the herpes simplex virus type 1 latency-associated transcript does not function as an antisense repressor of ICP0 in nonneuronal cells. J Virol (2003) 0.86
Sox11 modulates brain-derived neurotrophic factor expression in an exon promoter-specific manner. J Neurosci Res (2012) 0.86
Gene therapy applications for the treatment of neuropathic pain. Expert Rev Neurother (2007) 0.86